National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Pertuzumab is licensed for the adjuvant treatment, in combination with trastuzumab and chemotherapy, of adult patients with HER2-positive breast cancer at high risk of recurrence.


NCPE Assessment Process Complete
Rapid review commissioned 01/06/2018
Rapid review completed 22/06/2018
Rapid Review outcome A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of pertuzumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 22/06/2018
Pre-submission consultation with Applicant 31/07/2018
Submission received from Applicant 14/09/2018
Preliminary review sent to Applicant 13/11/2018
Current Status Awaiting response from Applicant